PBR Nachrichten

 

AstraZeneca will obtain a licence to develop, manufacture and commercialise the phosphodiesterase 3/4 (PDE3/4) inhibitor, TQC3721, outside China. The agreement also covers certain future development programmes on an The post Sino and AstraZeneca sign licence agreement for TQC3721 appeared first on Pharmaceutical Business review....

Facilitated by Ramot, which manages technology transfer for Tel Aviv University, the agreement will combine computational and experimental tools for academic teams and scientific entrepreneurs seeking to advance The post Evogene and Tel Aviv University launch drug discovery initiative appeared first on Pharmaceutical Business review....

The FDA's Office of Orphan Products Development and Office of Pediatric Therapeutics granted this status to the therapy. CMT2S is a rare, inherited neurological condition that progressively causes The post FDA grants rare paediatric designation to Vanda's CMT2S therapy appeared first on Pharmaceutical Business review....

Under this collaboration, Biocytogen will offer access to up to five bispecific antibodies via its RenLite platform. Whitehawk Therapeutics will assess them in conjunction with its own ADC The post Biocytogen and Whitehawk partner to develop ADCs appeared first on Pharmaceutical Business review....

Approved unanimously by both companies' boards, the acquisition will see Vertex pay $85.00 per share in cash for all outstanding shares of Crinetics. It is expected to close The post Vertex signs agreement to acquire Crinetics for $10bn appeared first on Pharmaceutical Business review....

The decision is based on data from the pivotal Phase III EPCORE FL-1 trial, which assessed the efficacy and safety of the fixed-duration Tepkinly plus lenalidomide and rituximab The post EC approves AbbVie's Tepkinly combination for follicular lymphoma appeared first on Pharmaceutical Business review....

The deal includes an upfront payment of $1.1bn and up to $400m in potential milestone payments. It is expected to close in the second half of 2026, pending The post Novartis to acquire Myricx Bio in up to $1.5bn deal appeared first on Pharmaceutical Business review....

UniD Manufacturing's expertise includes advanced polymer systems used in complex delivery formats such as implants and vaginal rings. Besins Healthcare will acquire UniD's site in Seraing, Belgium. A The post Besins Healthcare boosts drug delivery portfolio with UniD deal appeared first on Pharmaceutical Business review....

The project will involve collaboration with global health organisation PATH and consulting firm Slalom. The initiative seeks to create a platform that uses AI to analyse a wide The post SK bioscience to lead Gates Foundation-funded ROTOR project appeared first on Pharmaceutical Business review....

With this decision, Itvisma becomes the only gene replacement therapy which is currently approved for this wider patient population within the EU. Itvisma works by providing a functional The post European Commission approves Novartis' Itvisma to treat SMA appeared first on Pharmaceutical Business review....

Under the agreement, Insilico will lead efforts using AI to identify molecules that meet predefined scientific and early development criteria. Takeda will take the lead in advancing selected The post Insilico Medicine, Takeda partner on AI-driven drug discovery appeared first on Pharmaceutical Business review....

The deal includes a strategic equity investment by AimedBio in Inocras and a joint research agreement between the two companies. Additionally, the whole genome sequencing (WGS) capabilities of The post Inocras, AimedBio team up for cancer treatments appeared first on Pharmaceutical Business review....

This decision was issued in a Complete Response Letter (CRL) which cited deficiencies at a third-party manufacturing facility producing OLC. The FDA did not raise concerns related to The post US FDA rejects approval of Unicycive's kidney disease therapy appeared first on Pharmaceutical Business review....

Under this agreement, Innovent will handle the marketing, distribution and promotion of the product within the region, while Eli Lilly will continue to manage manufacturing, supply and development. Verzenios The post Eli Lilly and Innovent agree Verzenios commercialisation deal in China appeared first on Pharmaceutical Business review....

The MOIP has issued Patent Number 10-2960889, providing protection for Anixa's breast cancer vaccine approach in South Korea through 2040. This specific composition-of-matter patent is exclusively licensed from The post Anixa Biosciences secures Korean patent for breast cancer vaccine appeared first on Pharmaceutical Business review....

Under the terms of the deal, Theravance Biopharma shareholders will receive $17 per share. Shareholders will also receive a contingent value right (CVR) entitling them to 80% of The post Zymeworks agrees to buy Theravance Biopharma for $929m appeared first on Pharmaceutical Business review....

The FDA has requested further information, primarily focusing on the manufacturing control strategy of the biological component of NASP and on deficiencies related to contract manufacturing facilities. It The post FDA issues complete response letter to Sobi's NASP for gout appeared first on Pharmaceutical Business review....

This Jaypirca CHMP recommendation for CLL applies across all lines of therapy, regardless of previous Bruton tyrosine kinase (BTK) inhibitor treatment. Following this recommendation, the Jaypirca application moves The post Lilly's Jaypirca receives CHMP positive opinion for CLL in Europe appeared first on Pharmaceutical Business review....

The initial phase of the partnership, valued at up to $15m and running until 2027, may be expanded if scientific milestones are met and both parties agree. The The post Immunai and Boehringer partner to identify T-cell targets appeared first on Pharmaceutical Business review....

Ionis will retain the responsibility for commercialising the RNA-targeted medicine within the US and will remain the global lead for development activities. Under the agreement, Recordati will handle regulatory The post Ionis grants Recordati rights to zilganersen for Alexander disease appeared first on Pharmaceutical Business review....